Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.

Kernan NA, Richardson PG, Smith AR, Triplett BM, Antin JH, Lehmann L, Messinger Y, Liang W, Hume R, Tappe W, Soiffer RJ, Grupp SA.

Pediatr Blood Cancer. 2018 Jun 6:e27269. doi: 10.1002/pbc.27269. [Epub ahead of print]

PMID:
29873895
2.

Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

Richardson PG, Triplett BM, Ho VT, Chao N, Dignan FL, Maglio M, Mohty M.

Expert Rev Clin Pharmacol. 2018 Feb;11(2):113-124. doi: 10.1080/17512433.2018.1421943. Epub 2018 Jan 5. Review.

PMID:
29301447
3.

Chronic disease burden and frailty in survivors of childhood HSCT: a report from the St. Jude Lifetime Cohort Study.

Eissa HM, Lu L, Baassiri M, Bhakta N, Ehrhardt MJ, Triplett BM, Green DM, Mulrooney DA, Robison LL, Hudson MM, Ness KK.

Blood Adv. 2017 Nov 7;1(24):2243-2246. doi: 10.1182/bloodadvances.2017010280. eCollection 2017 Nov 14.

4.

Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared with CD3-targeted T-cell depletion.

Triplett BM, Muller B, Kang G, Li Y, Cross SJ, Moen J, Cunningham L, Janssen W, Mamcarz E, Shook DR, Srinivasan A, Choi J, Hayden RT, Leung W.

Transpl Infect Dis. 2018 Feb;20(1). doi: 10.1111/tid.12823. Epub 2018 Jan 16.

PMID:
29178554
5.

Treatment intensity and symptom burden in hospitalized adolescent and young adult hematopoietic cell transplant recipients at the end of life.

Snaman JM, Talleur AC, Lu J, Levine DR, Kaye EC, Sykes A, Lu Z, Triplett BM, Baker JN.

Bone Marrow Transplant. 2018 Jan;53(1):84-90. doi: 10.1038/bmt.2017.187. Epub 2017 Nov 13.

6.

Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.

Talleur AC, Triplett BM, Federico S, Mamcarz E, Janssen W, Wu J, Shook D, Leung W, Furman WL.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1910-1917. doi: 10.1016/j.bbmt.2017.07.011. Epub 2017 Jul 18.

PMID:
28733263
7.

Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.

Alexander TB, Wang L, Inaba H, Triplett BM, Pounds S, Ribeiro RC, Pui CH, Rubnitz JE.

Cancer. 2017 Oct 1;123(19):3791-3798. doi: 10.1002/cncr.30791. Epub 2017 May 30.

PMID:
28556917
8.

Human memory CD8 T cell effector potential is epigenetically preserved during in vivo homeostasis.

Abdelsamed HA, Moustaki A, Fan Y, Dogra P, Ghoneim HE, Zebley CC, Triplett BM, Sekaly RP, Youngblood B.

J Exp Med. 2017 Jun 5;214(6):1593-1606. doi: 10.1084/jem.20161760. Epub 2017 May 10.

9.

Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.

Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, Lehmann L, Miloslavsky M, Hume R, Hannah AL, Nejadnik B, Soiffer RJ.

Br J Haematol. 2017 Jul;178(1):112-118. doi: 10.1111/bjh.14727. Epub 2017 Apr 26.

10.

Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.

Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, Lehmann L, Shore T, Iacobelli M, Miloslavsky M, Hume R, Hannah AL, Nejadnik B, Soiffer RJ; Defibrotide Study Group.

Biol Blood Marrow Transplant. 2017 Jun;23(6):997-1004. doi: 10.1016/j.bbmt.2017.03.008. Epub 2017 Mar 8.

11.

Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.

Triplett BM, Kuttab HI, Kang G, Leung W.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2148-2153. doi: 10.1016/j.bbmt.2015.08.013. Epub 2015 Aug 14.

12.

Rapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic malignancies.

Triplett BM, Shook DR, Eldridge P, Li Y, Kang G, Dallas M, Hartford C, Srinivasan A, Chan WK, Suwannasaen D, Inaba H, Merchant TE, Pui CH, Leung W.

Bone Marrow Transplant. 2015 Jul;50(7):1012. doi: 10.1038/bmt.2015.139. No abstract available.

PMID:
26130176
13.

Natural killer cell therapy in children with relapsed leukemia.

Rubnitz JE, Inaba H, Kang G, Gan K, Hartford C, Triplett BM, Dallas M, Shook D, Gruber T, Pui CH, Leung W.

Pediatr Blood Cancer. 2015 Aug;62(8):1468-72. doi: 10.1002/pbc.25555. Epub 2015 Apr 30.

14.

Rapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic malignancies.

Triplett BM, Shook DR, Eldridge P, Li Y, Kang G, Dallas M, Hartford C, Srinivasan A, Chan WK, Suwannasaen D, Inaba H, Merchant TE, Pui CH, Leung W.

Bone Marrow Transplant. 2015 Jul;50(7):968-77. doi: 10.1038/bmt.2014.324. Epub 2015 Feb 9. Erratum in: Bone Marrow Transplant. 2015 Jul;50(7):1012.

15.

Haploidentical stem cell transplantation augmented by CD45RA negative lymphocytes provides rapid engraftment and excellent tolerability.

Shook DR, Triplett BM, Eldridge PW, Kang G, Srinivasan A, Leung W.

Pediatr Blood Cancer. 2015 Apr;62(4):666-73. doi: 10.1002/pbc.25352. Epub 2015 Jan 5.

PMID:
25559618
16.

Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia.

Srinivasan A, Panetta JC, Cross SJ, Pillai A, Triplett BM, Shook DR, Dallas MH, Hartford C, Sunkara A, Kang G, Jacobsen J, Choi J, Leung W.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1224-8. doi: 10.1016/j.bbmt.2014.04.020. Epub 2014 Apr 23.

17.

Fludarabine-induced severe necrotizing leukoencephalopathy in pediatric hematopoietic cell transplantation.

Helton KJ, Patay Z, Triplett BM.

Bone Marrow Transplant. 2013 May;48(5):729-31. doi: 10.1038/bmt.2012.196. Epub 2012 Oct 22. No abstract available.

PMID:
23085831
18.

Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors.

Shook DR, Triplett BM, Srinivasan A, Hartford C, Dallas MH, Pillai A, Laver J, Leung W.

Biol Blood Marrow Transplant. 2013 Feb;19(2):291-7. doi: 10.1016/j.bbmt.2012.10.001. Epub 2012 Oct 9.

19.

Longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation.

Inaba H, Yang J, Kaste SC, Hartford CM, Motosue MS, Chemaitilly W, Triplett BM, Shook DR, Pui CH, Leung W.

J Clin Oncol. 2012 Nov 10;30(32):3991-7. doi: 10.1200/JCO.2011.40.0457. Epub 2012 Oct 1.

20.

Effects of conditioning regimens and T cell depletion in hematopoietic cell transplantation for primary immune deficiency.

Triplett BM, Wang C, Yang J, Dallas M, Hartford C, Howard V, Pillai A, Shook D, Srinivasan A, Laver J, Leung W.

Biol Blood Marrow Transplant. 2012 Dec;18(12):1911-20. doi: 10.1016/j.bbmt.2012.07.014. Epub 2012 Jul 27.

21.

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.

Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Shook D, Rubnitz JE, Sandlund JT, Jeha S, Inaba H, Ribeiro RC, Handgretinger R, Laver JH, Campana D.

Blood. 2012 Jul 12;120(2):468-72. doi: 10.1182/blood-2012-02-409813. Epub 2012 Apr 19.

22.

Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation.

Inaba H, Hartford CM, Pei D, Posner MJ, Yang J, Hayden RT, Srinivasan A, Triplett BM, McCulllers JA, Pui CH, Leung W.

Br J Haematol. 2012 Jan;156(1):109-17. doi: 10.1111/j.1365-2141.2011.08913.x. Epub 2011 Oct 24.

23.

High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.

Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K, Rubnitz JE, Sandlund JT, Ribeiro RC, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Handgretinger R, Laver JH, Pui CH.

Blood. 2011 Jul 14;118(2):223-30. doi: 10.1182/blood-2011-01-333070. Epub 2011 May 25.

24.

Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies.

Triplett BM, Horwitz EM, Iyengar R, Turner V, Holladay MS, Gan K, Behm FG, Leung W.

Leukemia. 2009 Jul;23(7):1278-87. doi: 10.1038/leu.2009.21. Epub 2009 Feb 12.

Supplemental Content

Loading ...
Support Center